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Abstract
Introduction: Sepsis-associated encephalopathy (SAE) is a diffuse cerebral dysfunction induced by the immuno-
inflammatory response to infection. Elevated levels of the brain-specific S100B protein are present in many septic 
patients and reflect the severity of SAE. Adjunctive treatment with drotrecogin alfa (activated) (DrotAA), the human 
recombinant form of activated protein C, has been shown to improve mortality in patients with severe sepsis-induced 
organ failure. We studied the effect of DrotAA on S100B levels in patients with acute septic shock who presented with 
increased baseline values of this biomarker.
Methods: All patients received standard goal-directed resuscitation treatment. Patients with pre-existing or acute 
neurological disorders were excluded. Based on the Glasgow coma scale (GCS), patients were classified into two 
groups: GCS ≥ 13 and GCS <13. DrotAA was given as a continuous infusion of 24 μg/kg/h for 96 h. S100B was measured 
before sedation and the start of DrotAA (0 h) and at 32 h, 64 h and 96 h and at corresponding time points in patients 
not treated with DrotAA. The lower limit of normal was < 0.5 μg/L.
Results: Fifty-four patients completed the study. S100B was increased in 29 (54%) patients. Twenty-four patients (9 
with GCS ≥ 13 and 15 with GCS <13) received DrotAA. S100B levels in DrotAA-treated patients with a GCS <13, though 
higher at baseline than in untreated subjects (1.21 ± 0.22 μg/L vs. 0.95 ± 0.12 μg/L; P = 0.07), progressively and 
significantly decreased during infusion (0.96 ± 0.22 μg/L at 32 h, P = 0.3; 0.73 ± 0.12 μg/L at 64 h, P < 0.05; and 0.70 ± 
0.13 μg/L at 96 h, P < 0.05 vs. baseline). This patient group had also significantly lower S100B values at 64 h and at 96 h 
than their untreated counterparts. In the patients with a GCS ≥ 13, S100B levels were not influenced by DrotAA 
treatment.
Conclusions: S100B-positivity is present in more than half of the patients with septic shock. When increased S100B 
levels are used as a surrogate for SAE, adjunctive DrotAA treatment seems to beneficially affect the evolution of severe 
SAE as discriminated by an admission GCS <13.
Introduction
Sepsis-associated encephalopathy (SAE) is a diffuse cere-
bral dysfunction accompanying an evolving septic state.
The pathophysiological alterations underlying SAE are
incompletely understood. Basically, there is no direct
infection of the brain. Rather, both inflammatory and
non-inflammatory processes are involved that induce
blood-brain barrier breakdown, cerebrovascular
endothelial activation, deregulation of brain metabolic
pathways, and brain cell apoptosis [1].
Activated protein C (APC) plays a key role in the pres-
ervation of endothelial function and microvascular perfu-
s i o n  d u r i n g  s e v e r e  s e p s i s  a n d  s e p t i c  s h o c k .  H e n c e ,  a
dysfunctional protein C pathway is thought to contribute
largely to sepsis-induced microvascular and subsequent
organ failure. Drotrecogin alfa (activated) (DrotAA), a
recombinant human APC, has been shown to improve
the microcirculation in vivo. DrotAA also binds directly
to specific receptors on endothelial and inflammatory
cells, thereby modulating and downregulating inflamma-
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tory and apoptotic processes [2]. Adjuvant therapy with
DrotAA has been shown to significantly reduce mortality
in adult patients with severe sepsis [3]. Survival rate was
highest in the most severely ill patients and largely driven
by a more rapid improvement of cardiovascular and
respiratory failure [4].
We have previously demonstrated that levels of the
highly brain-specific protein S100B were increased in low
consciousness SAE, suggesting a possible use for this pro-
tein as a biomarker of SAE [5]. We investigated whether
and how S100B serum levels, when used as a biochemical
surrogate for SAE, were influenced when DrotAA was
added to standard treatment in patients with septic
shock.
Materials and methods
The study was approved by the Ethics Committee of our
hospital and was conducted in compliance with the Dec-
laration of Helsinki. Patients with pneumonia-induced
septic shock were included after informed consent was
obtained from a next of kin. Pneumonia was either acute-
onset community-acquired or nosocomial and character-
ized by bilateral infiltrates on chest x-ray and a PaO2/FiO2
ratio <300. Septic shock was defined as sepsis-induced
hypotension along with the presence of perfusion abnor-
malities, initially not responding to adequate fluid resus-
citation. Patients were excluded when one of the
following criteria was present: age <18 years; pregnancy
or nursing state; renal and hepatic failure; primary central
nervous disorders (for example, meningitis, neoplasm,
stroke, head injury, known epilepsy); peripheral or critical
illness polyneuropathy; alcohol or drug abuse; Wernicke
encephalopathy; acute mental deterioration secondary to
non-septic metabolic disorders with organ dysfunction;
sepsis associated with dismal prognosis and imminent
death; and sepsis occurring within two weeks after car-
diac resuscitation, severe burns, trauma, orthopaedic sur-
gery, cardiac bypass surgery, or neurosurgery.
Resuscitation aimed to obtain and maintain a mean
arterial blood pressure ≥ 70 mmHg, a ScvO2 >70% and a
correct cardiac output (confirmed by transoesophageal
echocardiography). To achieve these goals, all patients
received colloid and crystalloid volume suppletion and, if
needed, dobutamine (up to 20 μg/kg/minute) and/or nor-
epinephrine (up to 1.5 μg/kg/minute). All patients were
mechanically ventilated under continuous infusion with a
combination of propofol (up to 12 mg/kg/h) or midazo-
lam (up to 0.3 mg/kg/h) and fentanyl (up to 0.05 mg/kg/
minute). Cisatracurium (1 to 2 mg/kg/minute) was added
to obtain adequate patient-ventilator synchronization
when necessary. Patients were treated with empirical
broad-spectrum antibiotic therapy, which was adjusted
according to culture results and received stress doses of
hydrocortisone (100 mg loading dose followed by a con-
tinuous infusion of 0.18 mg/kg/h). Insulin was infused in
all patients to keep glycaemia between 100 and 150 mg/
dL. Patients were not randomized whether or not to
receive DrotAA. Prescription of DrotAA followed
national guidelines but the decision to start the drug was
left at the discretion of the attending physician. When
DrotAA was given, it was administered as a 24-h continu-
ous infusion of 24 μg/kg/minute during four consecutive
days.
In all patients, the Glasgow Coma Scale (GCS) was
assessed before tracheal intubation and start of sedation.
Patients were divided into two groups according to this
baseline GCS being either >13 or <13. A GCS cut-off at
13 was chosen based on the observations of Eidelman et
al. who found a three-fold increase in mortality when the
GCS decreased below 13 [6]. Patients with a GCS <13
underwent a contrast computed brain tomography (Sie-
mens, Sensation 16 Multislice, Forchheim, Germany) to
exclude pre-existing organic or vascular cerebral lesions.
A lumbar puncture was performed in all patients with a
GCS ≤ 8 to exclude brain or meningeal infection.
Blood was drawn from a radial arterial catheter for
measurement of S100B before the start of DrotAA infu-
sion (0 h) and at three distinct time points (32 h, 64 h, and
96 h) thereafter. In patients who did not receive DrotAA,
blood for S100B determination was taken at correspond-
ing time points. All samples were immediately centri-
fuged and aliquoted at -70°C until analysis. S100B was
measured with a monoclonal two-site immunoradiomet-
ric assay to detect the S100B subunit (Sangtec 100,
Sangtec Medical AB, Dietzenbach, Germany). Test
imprecision between days was <6%, and the lower limit of
normal value was < 0.5 μg/L.
The study was discontinued in patients who developed
significant renal impairment (defined as a two-fold
increase of baseline serum creatinine or the need to start
renal replacement therapy) during the study period.
Patients who survived at least 96 h following enrolment
in the study were evaluated. ICU and hospital mortality
were defined as being alive respectively at ICU discharge
and at the end of hospital stay.
SPSS package version 13.0 for Windows (SPSS Inc, Chi-
cago, IL, USA) was used for statistical analysis. Chi-
square and Student's t- test were used to evaluate differ-
ences in age, gender, mortality and Sequential Organ Fail-
ure Assessment (SOFA) and Acute Physiology and
Chronic Health Evaluation (APACHE) II scores between
patients with GCS ≥ and <13. S100B levels between both
GCS groups were compared using a one-way analysis of
variance for repeated measurements followed by Bonfer-
roni test for multiple comparisons. Data were expressed
as means ± SD or means ± SEM. Statistical significance
was accepted at P < 0.05.Spapen et al. Critical Care 2010, 14:R54
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Results
Fifty-four patients (33 men; 21 women) completed the
study protocol. At study entry, 23 had a GCS ≥ 13 and 31
had a GCS <13. S100B levels were elevated in 29 (54%)
patients and exceeded 1 μg/L for at least one measure-
ment in 12 (22%) patients. Sixty-five percent of patients
with a GCS <13 and 45% of patients with a GCS ≥ 13 had
increased S100B levels.
Patients with a GCS <13 had significantly higher
APACHE II scores, baseline SOFA scores and higher
baseline S100B values than those with a GCS ≥ 13 (Table
1).
Twenty-four patients (9 with GCS ≥ 13 and 15 with
GCS <13) received DrotAA. In the group of patients with
a GCS <13, those who received DrotAA tended to have
higher baseline S100B levels than their untreated coun-
terparts (1.21 ± 0.22 vs 0.95 ± 0.12 μg/L; P = 0.07). S100B
levels progressively decreased during DrotAA infusion in
patients with a GCS <13 only (0.96 ± 0.22 μg/L at 32 h;
0.73 ± 0.12 μg/L at 64 h; 0.70 ± 0.13 μg/L at 96 h; all
means ± standard error of the mean (SEM); P respectively
= 0.3; < 0.05; and < 0.05 compared to baseline). Com-
pared to untreated patients, those who received DrotAA,
had significantly lower S100B values at 64 h (1.34 ± 0.12
vs. 0.73 ± 0.12 μg/L; P < 0.05) and at 96 h (1.07 ± 0.13 vs.
0.70 ± 0.13 μg/L; P < 0.05) (Figure 1, upper panel). In con-
trast, patients with a GCS ≥ 13, had comparable S100B
levels within and between groups, that were not affected
by DrotAA treatment (Figure 1, lower panel).
Global ICU and in-hospital mortality were high
(respectively 59% and 76%) and did not differ between
DrotAA-treated and -untreated patients (ICU mortality
62.5% vs. 57%; hospital mortality 75% vs. 77%; both P >
0.05). Mortality was also not different between patients
with GCS values above or below 13, regardless DrotAA
was given or not (Table 1).
Discussion
Patients with septic shock frequently have alterations in
consciousness ranging from mild stupor to coma which
cannot be attributed to brain lesions, haemodynamic
instability or metabolic disorders [6]. This so-called SAE
remains often unnoticed within the clinical spectrum of
septic shock that is mostly dominated by life-threatening
cardiovascular, respiratory, and renal complications.
However, SAE is to be considered as a distinct sepsis-
induced organ dysfunction since it is characterized by
local expression of pro-inflammatory cytokines in the
absence of gross abnormalities of cerebral blood flow or
direct infectious involvement of the brain. The
pathophysiology of SAE is multifactorial and features
cerebrovascular endothelial dysfunction, blood-brain
barrier disruption and abnormal neurotransmitter pat-
terns. Main pathological findings include haemorrhagic
lesions, microthrombi and abscesses, cyto- and vasogenic
oedema, and multifocal necrotizing leukoencephalopathy
[1,7,8]. Also, neuronal and microglial apoptosis is
detected in brain areas that are involved in the neuro-
endocrine and behavioural response to stress [9].
Bedside diagnosis and follow-up of SAE are cumber-
some. Clinical neurological evaluation, essentially based
on GCS assessment, is difficult and rapidly becomes
futile when analgesic sedation is started. Daily interrup-
tion of sedation is often not feasible during treatment of
pneumonia-induced septic shock and may also confound
SAE with sedation withdrawal effects. Electroencepha-
lography (EEG) is a more sensitive method to detect brain
dysfunction. However, EEG patterns in sepsis are ham-
pered by sedation, show a broad range of interindividual
variability, and are difficult to quantify. Also, S100B levels
do not correlate with either the GCS or EEG patterns in
septic patients [10]. The recording of somatosensory
evoked potentials (SEP) provides an elegant and reliable
estimation of the severity of SAE [11]. Still, this technique
is difficult to use in routine and the relationship between
the degree of SEP impairment and corresponding S100B
levels in SAE remains to be determined. Cerebrospinal
fluid assay and neuroimaging cannot be considered mon-
itoring tools. With the exception of specific situations
Figure 1 S100B levels in patients with GCS <13 and GCS ≥ 13, with 
or without DrotAA treatment. * P < 0.05 as compared to baseline 
S100B levels in DrotAA-treated patients; °P < 0.05 DrotAA-treated vs. -
untreated patients. Values are means ± SEM DrotAA: drotrecogin alfa 
(activated); GCS: Glasgow Coma Scale; SEM: standard error of the 
mean.
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(seizures, focal neurological signs, suspicion of meningeal
or cerebral infection), it is also impossible to correctly
time these interventions during the course of illness.
S100B is a low-molecular weight, calcium-binding pro-
tein secreted by glial and Schwann cells. S100B is released
following brain injury of various aetiology. Serum levels
of this biomarker correlate positively with the degree of
brain injury and neuronal apoptosis and predict the out-
come [12-14]. We have previously shown that S100B lev-
els in severe sepsis better reflected the presence and
prognosis of low consciousness SAE than the GCS. S100B
levels were increased in 42% of patients, exceeding 1 μg/L
in 11%. S100B levels between 0.06 and 2 μg/L were typi-
cally associated with white matter lesions which are
thought to represent the pathological substrate of SAE
[5]. In the present study, a higher incidence of S100B ele-
vation was found which probably relates to a higher
severity of illness in the patient population studied. The
observed high mortality rate is also in line with our ear-
lier findings, indicating a 70% mortality in S100B-positive
patients with severe sepsis [5]. It could be argued that the
observed high S100B levels might be, at least partially, of
extracerebral origin. This is unlikely since common
sources of S100B release such as renal failure and surgical
tissue injury were either excluded or avoided. Whether
serum S100B elevation in sepsis always reflects blood-
brain barrier disruption is difficult to prove. Data are con-
flicting with some authors demonstrating high levels of
S100B [15] while others report no evidence of S100B
increase [16] in the cerebrospinal fluid. We were unable
to measure S100B in the cerebrospinal fluid because lum-
bar puncture is an absolute contraindication during Dro-
tAA infusion due to the bleeding risk.
A specific treatment for SAE does not exist. The out-
come of SAE is considered to be dependent on prompt
and appropriate treatment of the septic process as a
whole. Besides control of infection, this also implies man-
agement of organ failure, correction of metabolic distur-
bances, and avoidance of neurotoxic drugs. There is no
clinical evidence that adjuvant therapy such as strict gly-
caemic control with insulin, stress doses of steroids or
APC either reduce the incidence or influence the severity
and evolution of SAE. Insulin may be neuroprotective as
it can prevent hyperglycaemia-induced oxidative stress
and apoptotic cell death. However, anticipating insulin
effects on SAE is impossible due to the complexity of
cerebral glucose metabolism and the high variability in
glucose levels between patients. Moreover, intensive
insulin therapy does not improve outcome of patients
with ischaemic [17] or traumatic [18] brain injury and
significantly increases the risk of hypoglycaemia which,
by itself, can induce neurocognitive dysfunction [19]. Ste-
roids can decrease systemic inflammation and high doses
are known to reduce brain oedema and to restore blood
brain barrier function [20]. However, high-dose steroids
are associated with higher mortality and increase the risk
for secondary infection and hepatorenal dysfunction
[21,22]. Stress doses, as given in our patients, have not
been shown to reduce serum S100B in septic shock [23].
APC, commercialized as DrotAA, is approved by both
the American and European Drug Agencies as an adjunc-
tive treatment of severe sepsis in patients with organ fail-
Table 1: Patient characteristics and mortality
GCS ≥ 13 GCS <13
Gender (M/F; n) 12/11 21/10
Age (years; mean ± SD) 69 ± 13 72 ± 10
APACHE II score (mean ± SD) 17 ± 4 * 25 ± 7
Baseline SOFA score (mean ± SD) 8 ± 2 * 10 ± 3
Baseline S100B (μg/L; mean ± SEM) 0.70 ± 0.08° 0.96 ± 0.15
ICU mortality (n; %)†
DrotAA 6 (67) 10 (67)
No DrotAA 7 (50) 9 (56)
Hospital mortality (n; %)
DrotAA 6 (67) 13 (86)
No DrotAA 10 (71) 12 (75)
* P < 0.05, °P = 0.05 as compared to patients with GCS <13
† number and percentage of DrotAA-treated or -untreated patients who died
APACHE: Acute Physiology and Chronic Health Evaluation; DrotAA: drotrecogin alfa (activated); F: female; ICU: intensive care unit; M: male; 
SOFA: Sequential Organ Failure AssessmentSpapen et al. Critical Care 2010, 14:R54
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u r e  a n d / o r  a t  h i g h  r i s k  o f  d e a t h .  I n d e p e n d e n t  o f  i t s
clinically apparent anticoagulant activity, APC directly
interferes at the interface between the (micro)vascular
endothelium and the innate immune response. The bind-
ing of APC on endothelial and inflammatory cell recep-
tors exerts pleiotropic in vitro intra- and intercellular
effects, altering gene expression profiles, inhibiting apop-
tosis and down-regulating inflammation. As a result,
APC preserves, protects and probably even restores
endothelial function which may attenuate ongoing and
prevent further organ damage [24]. This concept is cor-
roborated by the proven benefit of adjunctive DrotAA
treatment on cardiovascular, respiratory and haematolog-
ical disorders in severe clinical sepsis [4]. The effect of the
drug on sepsis-induced renal and cerebral dysfunction,
however, is less evident, mainly because sensitive param-
eters for objective evaluation of these organ systems are
lacking.
The cerebral effects of APC become progressively elu-
cidated. In mice, APC crosses the blood-brain barrier via
binding on the endothelial protein C receptor, acts
directly on neurons, microglial cells, microvessels and
motor neurons [25], and protects stressed brain endothe-
lial cells from hypoxic/ischaemic damage [26]. In a rat
model of periventricular leukomalacia, an injury that
mimics the pathophysiological findings of SAE, treat-
ment with APC was associated with less endotoxin-
induced white matter and myelination deficits. This pro-
tective effect was associated with a decrease in neuronal
apoptosis and reduced local expression of pro-inflamma-
tory cytokines [27]. Finally, APC has neuroprotective
activity in human ischaemic brain [28] by regulating cyto-
solic Ca2+ flux and blocking apoptosis in brain endothelial
cells [29]. The present study suggests that APC may
attenuate SAE but only in patients with clinically more
severe neurological dysfunction. This is in line with pre-
vious observations showing that APC tends to be more
effective in the most critically ill patients.
Our study has important limitations. Though repre-
senting a rather homogenous septic shock population,
the number of patients is small. This precludes a reliable
assessment of any possible impact of structural compo-
nents of the sepsis resuscitation protocol (amount and
type of fluid, catecholamine use, sedation level, glycaemic
control, nutritional status) on the evolution of SAE.
Patients were also studied for a short period of time and
S100B behaviour after DrotAA treatment had been
stopped is unknown. The decrease in S100B in DrotAA-
treated patients was not paralleled by a decrease in mor-
tality. This suggests that the presumed attenuation of SAE
does not play a preponderant role in septic shock sur -
vival.
Conclusions
This study is the first to show a probable beneficial effect
of APC on the evolution of severe SAE, defined as an
admission GCS <13, in clinical septic shock. The useful-
ness of S100B as a serum biomarker for bedside diagnosis
of SAE and its role in the evaluation of specific treatment
effects on this particular condition merits further investi-
gation. Our findings also call for more comprehensive
experimental and clinical research to clarify the relation-
ship between S100B protein behaviour and the extent of
concomitant electrophysiological, cerebrovascular, and
neurohormonal alterations in severe clinical sepsis and
septic shock.
Key messages
▪ The S100B peptide is a potential serum biomarker
for bedside diagnosis and follow-up of sepsis-associ-
ated encephalopathy.
▪ Adjunctive treatment with activated protein C may
attenuate the encephalopathy that accompanies septic
shock. However, the beneficial effect is only present
in more severe encephalopathy and does not affect
mortality.
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